Cite
Ibrutinib for chronic graft-versus-host disease after failure of prior therapy.
MLA
Miklos, David, et al. “Ibrutinib for Chronic Graft-versus-Host Disease after Failure of Prior Therapy.” Blood, vol. 130, no. 21, Nov. 2017, pp. 2243–50. EBSCOhost, https://doi.org/10.1182/blood-2017-07-793786.
APA
Miklos, D., Cutler, C. S., Arora, M., Waller, E. K., Jagasia, M., Pusic, I., Flowers, M. E., Logan, A. C., Nakamura, R., Blazar, B. R., Yunfeng Li, Chang, S., Lal, I., Dubovsky, J., James, D. F., Styles, L., & Jaglowski, S. (2017). Ibrutinib for chronic graft-versus-host disease after failure of prior therapy. Blood, 130(21), 2243–2250. https://doi.org/10.1182/blood-2017-07-793786
Chicago
Miklos, David, Corey S. Cutler, Mukta Arora, Edmund K. Waller, Madan Jagasia, Iskra Pusic, Mary E. Flowers, et al. 2017. “Ibrutinib for Chronic Graft-versus-Host Disease after Failure of Prior Therapy.” Blood 130 (21): 2243–50. doi:10.1182/blood-2017-07-793786.